In vitro bioactivities of Codonopsis javanica root extract from Kon Tum province, Vietnam

Dangshen Codonopsis javanica exhibits invaluable medicinal properties in herbal remedies; however, there has currently not been much specific analysis of the phytochemicals and bioactivities of this plant. The root ethanol extract of C. javanica contains substances such as saponins, phenolic acids, terpenoids, and alkaloids. It displays an antibacterial effect against Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Bacillus cereus with the IC50 values of 150, 100, 150, and 90 μg/mL, respectively. The antioxidant capacity of the root extract was also observed with an IC50 value of 46.8 ± 6.8 μg/mL. Furthermore, the extract exhibits activity on human cancer cell lines HepG2 (IC50 = 83.6 ± 2.7 μg/mL) and MCF-7 (IC50 = 95.3 ± 2.3 μg/mL). Hence, this study provides the basic data for further research on the bioactivities of natural compounds of Dangshen C. javanica for the first time

Predominant HLA Alleles and Haplotypes in Mild Adverse Drug Reactions Caused by Allopurinol in Vietnamese Patients with Gout

Allopurinol (ALP) is commonly used as a drug for gout treatment. However, ALP is known to cause cutaneous adverse reactions (CARs) in patients. The HLA-B*58:01 allele is considered a biomarker of severe CAR (SCAR) in patients with gout, with symptoms of Stevens Johnson syndrome, and with toxic epidermal necrolysis. However, in patients with gout and mild cutaneous adverse drug reactions (MCARs), the role of HLA-allele polymorphisms has not been thoroughly investigated. In this study, 50 samples from ALP-tolerant patients and ALP-induced MCARs patients were genotyped in order to examine the polymorphisms of their HLA-A and HLA-B alleles. Our results showed that the frequencies of HLA-A*02:01/HLA-A*24:02 and HLA-A*02:01/HLA-A*29:01, the dual haplotypes in HLA-A, in patients with ALP-induced MCARs were relatively high, at 33.3% (7/21), which was HLA-B*58:01-independent, while the frequency of these dual haplotypes in the HLA-A locus in ALP-tolerant patients was only 3.45% (1/29). The HLA-B*58:01 allele was detected in 38% (8/21) of patients with ALP-induced MCARs, and in 3.45% (1/29) of ALP-tolerant patients. Notably, although HLA-B*58:01 may be a cause for the occurrence of MCARs in patients with gout, this correlation was not as strong as that previously reported in patients with SCAR. In conclusion, in addition to the HLA-B*58:01 allele, the presence of the dual haplotypes of HLA-A*02:01/HLA-A*24:02 and/or HLA-A*02:01/HLA-A*29:01 in the HLA-A locus may also play an important role in the appearance of ALP-induced MCARs in the Vietnamese population. The obtained primary data may contribute to the development of suitable treatments for patients with gout not only in Vietnam but also in other Asian countries